The cancer fortress is falling: lasers, AI, and cord-blood cells strike at once

The number still shocks oncologists: pancreatic cancer, the fifth-leading cause of cancer death in the United States, has stubbornly defied nearly every treatment thrown at it for decades. Its tumor microenvironment—a dense shield of fibrosis and inflammatory cells—acts like a fortress wall, protecting rogue cells from chemotherapy and immunotherapy alike.

Now, across more than half a dozen universities and hospitals, researchers are quietly dismantling that fortress from multiple angles at once.

At Sylvester Comprehensive Cancer Center in Miami, Dr. Jashodeep Datta and his team have found a master switch. By blocking a receptor called IL1RAP, published in JCI Insight, they disrupted the entire inflammatory network that helps pancreatic tumors resist treatment. In preclinical experiments, the approach shrank the tumor-protecting cells and fibrosis while supercharging cancer-fighting T cells. The work is moving toward a first-of-its-kind neoadjuvant clinical trial combining IL1RAP-targeted therapy with chemoimmunotherapy before surgery.

Meanwhile, at UCI Health's Chao Family Comprehensive Cancer Center in California, Dr. Nadine Abi-Jaoudeh is pointing actual lasers at the problem. In a first-in-human Phase I trial, she injects patients with the light-sensitive drug padeliporfin, then threads a balloon containing a laser into the tumor-encased blood vessel. When the laser switches on, it activates the drug and destroys the tumor surrounding the artery—clearing the way for a "lifesaving surgery" that was previously impossible.

At Mayo Clinic, artificial intelligence is reading the geography of the disease. Dr. Ryan Carr and his team found that how residual cancer is organized matters more than how much remains. Using AI-enabled spatial analysis of routine pathology slides, published in Clinical Cancer Research, they identified that patients with a more fragmented, intermixed pattern of cancer and stroma had earlier recurrence—a clue that could sharpen recurrence-risk estimates for the hardest-to-treat patients.

And in Los Angeles, UCLA researchers have turned cord blood into something extraordinary. They engineered ready-made T cells that attack solid tumors through two separate detection systems, going deeper than CAR-T therapy by recognizing protein fragments originating inside cancer cells. In mice, a single dose controlled cancer and extended survival—while avoiding graft-versus-host disease, the dangerous complication that has limited donor-derived T-cell therapies.

The progress isn't confined to cancer. At National Taiwan University Hospital, researchers found that patients with type 2 diabetes who started an SGLT-2 inhibitor within 30 days of hospital discharge after kidney injury had fewer serious kidney events (3.9%) than those who waited 31–90 days (6.2%), published in JAMA Network Open. Northwestern Medicine researchers identified a combination of olaparib with immunotherapy to overcome "immune-cold" prostate tumors, published in The Journal of Clinical Investigation.

Even the pandemic's shadow yielded a silver lining. Harvey L. Neiman Health Policy Institute and University of Pennsylvania researchers found that COVID-19 accelerated adoption of a five-treatment breast radiation regimen, with use jumping fivefold among Medicare beneficiaries—cutting treatment burden and health care spending. And a study in The American Journal of Pathology revealed that white blood cells enter the inflamed retina via the body's standard pathway, identifying PECAM as the gatekeeper and hinting at better-targeted treatments for eye inflammation.

None of this is a magic bullet. The KRAS-targeted therapies that are extending survival for some patients won't reach operable pancreatic cancer for years. Clinical trials take time. But the through-line is unmistakable: scientists are no longer attacking these diseases with one tool. They are rebuilding the immune system, reprogramming cells, targeting history's toughest tumors with lasers and algorithms—and, piece by piece, the fortress is falling.

These breakthroughs aren't confined to the lab bench. They ripple toward every person facing a diagnosis, every family holding its breath in a hospital corridor. The message is simple and real: the war on cancer and chronic disease is no longer a single front. It's a siege, coordinated from a dozen universities at once—and the walls are cracking.